evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

134 questions · 140 findings · 7 reviews · Other oral health

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 32 · 22.9%GRADE not reported 69 · 49.3%Very low 13 · 9.3%Low 4 · 2.9%Moderate 13 · 9.3%High 9 · 6.4%

Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…
    Studies not reported
    GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in mean duration of episodes compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interferon-alpha (topical lozenges) vs placebo

Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Kilic 2009 (interferon-alpha lozenges 1000 IU or 2000 IU vs placebo, 84 patients; high risk of selective reporting): the data presented did not allow analysis; authors reported no statistically significant difference…
    1 study · 84 participants
    GRADE not reported

Topical triamcinolone acetonide vs Phenytoin syrup mouthwash (30 mg in 5 mL)

Positive response (not defined) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Triamcinolone acetonide 0.1% ointment (topical) led to higher positive response (not defined) compared with phenytoin syrup mouthwash (30 mg in 5 mL); GRADE not reported.

1 finding from 1 review

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review

Sucralfate suspension (topical) vs Placebo suspension

Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Sucralfate suspension (topical) vs Placebo suspension

Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Sucralfate suspension (topical) vs Placebo suspension

Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Rebamipide (systemic; 300 mg daily) vs placebo

Global aphthae count and pain score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Matsuda 2003 (rebamipide 300 mg daily vs placebo, 35 patients; high risk of reporting bias; concomitant treatments): authors stated that rebamipide improved the global evaluation aphthae count and global evaluation…
    1 study · 35 participants
    GRADE not reported

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Interferon-alpha 1000 IU lozenges (topical) vs Interferon-alpha 2000 IU lozenges (topical)

Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Interferon-alpha dose comparison
    Kilic 2009 (interferon-alpha 1000 IU vs 2000 IU lozenges, 84 patients): the data presented did not allow analysis; authors reported no statistically significant difference in total ulcer burden between the two doses.
    1 study · 84 participants
    GRADE not reported

Thalidomide (systemic; 100 mg or 300 mg daily) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Males only
    Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
    1 study · 101 participants
    GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Number of painful days · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in number of painful days compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interferon-alpha (systemic) vs Placebo (subcutaneous)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms.
    1 study · 50 participants
    GRADE not reported

HAART regimen + topical treatment vs HAART alone

Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers

The review found no eligible studies for this question.

1 finding from 1 review
  • Topical treatments for HIV‐related oral ulcers 2012 · Cochrane All outcomes
    No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6…
    0 studies
    No studies found

Antiseptic mouthwash (e.g. chlorhexidine) vs Another topical agent or placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers

The review found no eligible studies for this question.

1 finding from 1 review
  • Topical treatments for HIV‐related oral ulcers 2012 · Cochrane All outcomes
    No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6…
    0 studies
    No studies found

Topical thalidomide vs Another topical agent or placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers

The review found no eligible studies for this question.

1 finding from 1 review
  • Topical treatments for HIV‐related oral ulcers 2012 · Cochrane All outcomes
    No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6…
    0 studies
    No studies found

HAART regimen + topical treatment vs HAART alone

Healing of ulceration · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers

The review found no eligible studies for this question.

1 finding from 1 review
  • Topical treatments for HIV‐related oral ulcers 2012 · Cochrane All outcomes
    No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6…
    0 studies
    No studies found